Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide

Rinehart, 1983, Antiviral and antitumor compounds from tunicates, Fed Proc, 42, 87 Rinehart, 1981, Didemnins: antiviral and antitumor depsipeptides from a Caribbean tunicate, Science, 212, 933, 10.1126/science.7233187 Chun, 1986, Didemnin B: the first marine compound entering clinical trials as an antineoplastic agent, Invest New Drugs, 4, 279, 10.1007/BF00179597 Page, 1985, Effects of two new antineoplastic agents on blood coagulation, 26, 369 Li, 1984, Mechanism of action of didemnin B, a depsipeptide from the sea, Cancer Lett, 23, 279, 10.1016/0304-3835(84)90095-8 Crampton, 1984, Biochemical and cellular effects of didemnins A and B, Cancer Res, 44, 1796 Jiang, 1983, Antitumor activity of didemnin B in the human tumor stem cell assay, Cancer Chemother Pharmacol, 11, 1, 10.1007/BF00257406 Rossof, 1983, In vitro phase II study of didemnin B in human cancer, 24, 315 Rinehart, 1981, Marine natural products as sources of antiviral, antimicrobial, and antineoplastic agents, Pure Appl Chem, 53, 795, 10.1351/pac198153040795 Montgomery, 1985, Didemnin B: a new immunosuppressive cyclic peptide with potent activity in vitro and in vivo, Transplantation, 40, 49, 10.1097/00007890-198507000-00011 Stewart, 1986, Phase I evaluation of didemnin B (NCS 325319), 5, 33 Tony, 1986, Chromatographic assay for didemnin B and application to pharmacological studies, 27, 281 Phillips J, Schwartz R, Von Hoff DD. Distribution of didemnin B in blood cells and plasma. Manuscript in preparation.